These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27031038)

  • 1. Regression Discontinuity Design: Simulation and Application in Two Cardiovascular Trials with Continuous Outcomes.
    van Leeuwen N; Lingsma HF; de Craen AJ; Nieboer D; Mooijaart SP; Richard E; Steyerberg EW
    Epidemiology; 2016 Jul; 27(4):503-11. PubMed ID: 27031038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression discontinuity was a valid design for dichotomous outcomes in three randomized trials.
    van Leeuwen N; Lingsma HF; Mooijaart SP; Nieboer D; Trompet S; Steyerberg EW
    J Clin Epidemiol; 2018 Jun; 98():70-79. PubMed ID: 29486280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The regression discontinuity design showed to be a valid alternative to a randomized controlled trial for estimating treatment effects.
    Maas IL; Nolte S; Walter OB; Berger T; Hautzinger M; Hohagen F; Lutz W; Meyer B; Schröder J; Späth C; Klein JP; Moritz S; Rose M
    J Clin Epidemiol; 2017 Feb; 82():94-102. PubMed ID: 27865902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
    Albert MA; Staggers J; Chew P; Ridker PM;
    Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of controlled direct effects in time-varying treatments using structural nested mean models: application to a primary prevention trial for coronary events with pravastatin.
    Shinozaki T; Matsuyama Y; Ohashi Y
    Stat Med; 2014 Aug; 33(18):3214-28. PubMed ID: 24706589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
    Boekholdt SM; Sacks FM; Jukema JW; Shepherd J; Freeman DJ; McMahon AD; Cambien F; Nicaud V; de Grooth GJ; Talmud PJ; Humphries SE; Miller GJ; Eiriksdottir G; Gudnason V; Kauma H; Kakko S; Savolainen MJ; Arca M; Montali A; Liu S; Lanz HJ; Zwinderman AH; Kuivenhoven JA; Kastelein JJ
    Circulation; 2005 Jan; 111(3):278-87. PubMed ID: 15655129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian regression discontinuity designs: incorporating clinical knowledge in the causal analysis of primary care data.
    Geneletti S; O'Keeffe AG; Sharples LD; Richardson S; Baio G
    Stat Med; 2015 Jul; 34(15):2334-52. PubMed ID: 25809691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
    Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
    Simes J; Furberg CD; Braunwald E; Davis BR; Ford I; Tonkin A; Shepherd J
    Eur Heart J; 2002 Feb; 23(3):207-15. PubMed ID: 11792135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
    Zhou Z; Rahme E; Pilote L
    Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dirichlet process mixture models for regression discontinuity designs.
    Ricciardi F; Liverani S; Baio G
    Stat Methods Med Res; 2023 Jan; 32(1):55-70. PubMed ID: 36366738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating average cholesterol levels in patients with coronary heart disease.
    Lindbloom EJ
    J Fam Pract; 1999 Feb; 48(2):94-5. PubMed ID: 10037537
    [No Abstract]   [Full Text] [Related]  

  • 15. Cholesterol lowering with statins: how WOSCOPS confounded the skeptics.
    Shepherd J
    Atheroscler Suppl; 2007 Aug; 8(2):9-12. PubMed ID: 17586101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [WOSCOPS [West of Scotland Coronary Prevention Study]].
    Furutani N; Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():387-92. PubMed ID: 11347100
    [No Abstract]   [Full Text] [Related]  

  • 18. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes.
    Cheung BM; Lauder IJ; Lau CP; Kumana CR
    Br J Clin Pharmacol; 2004 May; 57(5):640-51. PubMed ID: 15089818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and secondary prevention of coronary heart disease.
    Ahmed M; Griffiths P
    Br J Community Nurs; 2004 Apr; 9(4):160-5. PubMed ID: 15150487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary and secondary prevention of coronary disease by statins].
    Ferrières J
    Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.